Cellular immune responses against the cancer-testis antigen SPAN-XB in healthy donors and patients with multiple myeloma

References

• Tricot G. Multiple myeloma. Hematology: Principles and Practice, R Hoffmann. Churchill Livingstone, New York 2000; 1398–1415
   Google Scholar
• Gregory W, Richards M, Malpas J. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992; 10: 334–342
   PubMed Web of Science ®Google Scholar
• Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994; 330: 484–489
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau J L, Stoppa A M, Sotto J J, Fuzibet J G, Rossi J F, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97
   PubMed Web of Science ®Google Scholar
• Goldschmidt H, Hegenbart U, Wallmeier M, Moos M, Haas R. High-dose chemotherapy in multiple myeloma. Leukemia 1997; 11(Suppl 5)S27–S31
   Google Scholar
• Hjorth M, Holmberg E, Rodjer S, Turesson I, Westin J, Wisloff F. Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades. Nordic Myeloma Study Group (NMSG). Eur J Haematol 1999; 62: 271–277
   PubMed Web of Science ®Google Scholar
• Moehler T M, Neben K, Benner A, Egerer G, Krasniqi F, Ho A D, et al. Salvage therapy for multiple myeloma with thalidomide anzd CED chemotherapy. Blood 2001; 98: 3846–3848
   PubMed Web of Science ®Google Scholar
• Barlogie B, Shaughnessy J, Zangari M, Tricot G. High-dose therapy and immunomodulatory drugs in multiple myeloma. Semin Oncol 2002; 29(6 Suppl 17)26–33. Review
   PubMed Web of Science ®Google Scholar
• Wen T, Mellstedt H, Jondal M. Presence of clonal T cell populations in chronic B lymphocytic leukemia and smoldering myeloma. J Exp Med 1990; 171: 659–666
   PubMed Web of Science ®Google Scholar
• Janson C H, Grunewald J, Österborg A, Dersimonian H, Brenner M B, Mellstedt H, et al. Predominant T cell receptor V gene usage in patients with abnormal clones of B cells. Blood 1991; 77: 1776–1780
   PubMed Web of Science ®Google Scholar
• Farace F, Orlanducci F, Dietrich P Y, Gaudin C, Angevin E, Courtier M H, Bayle C, Hercend T, Triebel F. T cell repertoire in patients with B chronic lymphocytic leukemia. J Immunol 1994; 153: 4281–4283
   PubMed Web of Science ®Google Scholar
• Moss P, Gillespie G, Frodsham P, Bell J, Reyburn H. Clonal populations of CD4+ and CD8+ T cells in patients with multiple myeloma and paraproteinemia. Blood 1996; 87: 3297–3306
   PubMed Web of Science ®Google Scholar
• Brown R D, Yuen E, Nelson M, Gibson J, Joshua D. The prognostic significance of T cells receptor β gene rearrangements and idiotype-reactive T cell in multiple myeloma. Leukemia 1997; 11: 1312–1317
   PubMed Web of Science ®Google Scholar
• Yi Q, Eriksson I, He W, Holm G, Mellstedt H, Österborg A. Idiotype-specific T lymphocytes in monoclonal gammopathies: evidence for the presence of CD4+ and CD8+ subsets. Br J Haematol 1997; 96: 338–345
   PubMed Web of Science ®Google Scholar
• Kay N, Leong T, Kyle R A, Greipp P, Van Ness B, Bone N, et al. Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myeloma patients, a Study of the Eastern Cooperative Oncology Group (E9487). Leuk Lymphoma 1999; 33: 127–133
   PubMed Web of Science ®Google Scholar
• Wen Y J, Barlogie B, Yi Q. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood 2001; 97: 1750–1755
   PubMed Web of Science ®Google Scholar
• Dhodapkar M V, Krasovsky J, Olson K. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad Sci USA 2002; 99: 13009–13013
   PubMed Web of Science ®Google Scholar
• Dhodapkar M V, Geller M D, Chang D H, Shimizu K, Fujii S, Dhodapkar K M, et al. A reversible defect in Natural Killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 2003; 197: 1667–1676
   PubMed Web of Science ®Google Scholar
• Massaia M, Dianzani U, Bianchi A, Camponi A, Boccasoro M, Pileri A. Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies. Clin Exp Immunol 1988; 73: 214–218
   PubMed Web of Science ®Google Scholar
• Dhodapkar M V, Krasovsky J, Osman K, Geller M. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med 2003; 11: 1753–1757
   Web of Science ®Google Scholar
• Ohtomo T, Sugamata Y, Ozaki Y, Ono K, Yoshimura Y, Kawai S, et al. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Commun 1999; 258: 583–591
   PubMed Web of Science ®Google Scholar
• Van Baren N, Brasseur F, Godelaine D, Hames G, Ferrant A, Lehmann F, et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 1999; 94: 1156–1164
   PubMed Web of Science ®Google Scholar
• Pellat-Deceunynck C, Mellerin M P, Labarrière N, Jego G, Moreau-Aubry A, Harousseau J L, et al. The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. Eur J Immunol 2000; 30: 803–809
   PubMed Web of Science ®Google Scholar
• Brossart P, Schneider A, Dill P, Schammann T, Grünebach F, Wirths S, et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC-1 specific cytotoxic T-lymphocytes. Cancer Res 2001; 61: 6846–6850
   PubMed Web of Science ®Google Scholar
• Choi C, Witzens M, Bucur M, Feuerer M, Sommerfeldt N, Trojan A, et al. Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood 2005; 105: 2132–2134
   PubMed Web of Science ®Google Scholar
• Westbrook V A, Schoppee P D, Diekman A B, Klotz K L, Allietta M, Hogan K T, et al. Genomic organization, incidence, and localization of the SPAN-X family of cancer-testis antigens in melanoma tumors and cell lines. Clin Cancer Res 2004; 10: 101–112
   PubMed Web of Science ®Google Scholar
• Zendman A J, Cornelissen I M, Weidle U H, Ruiter D J, van Muijen G N. CTp11, a novel member of the family of human cancer/testis antigens. Cancer Res 1999; 59: 6223–6229
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang Y, Liu H, Salati E, Chiriva-Internati M, Lim S H. Gene expression and immunologic consequence of SPAN-XB in myeloma and other hematologic malignancies. Blood 2003; 101: 955–960
   PubMed Web of Science ®Google Scholar
• Trojan A, Schultze J L, Witzens M, Vonderheide R H, Ladetto M, Donovan J W, et al. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med 2000; 6: 667–672
   PubMed Web of Science ®Google Scholar
• Bai L, Feuerer M, Beckhove P, Umansky V, Schirrmacher V. Generation of dendritic cells from human bone marrow mononuclear cells: advantages for clinical application in comparison to peripheral blood monocyte derived cells. Int J Oncol 2002; 20: 247–253
   PubMed Web of Science ®Google Scholar
• Feuerer M, Beckhove P, Bai L, Solomayer E F, Bastert G, Diel I J, et al. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 2001; 7: 452–458
   PubMed Web of Science ®Google Scholar
• Sahin U, Türeci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, et al. Human neoplasms elicit multiple specific immune responses in autologous host. Proc Natl Acad Sci USA 1995; 92: 11810–11813
   PubMed Web of Science ®Google Scholar
• Obata Y, Akahashi T, Tamaki H, Tominaga S, Murai H, Iwase T, et al. Identification of cancer antigens in breast cancer by the SEREX expression cloning method. Breast Cancer 1999; 6: 305–311
   PubMedGoogle Scholar
• Krackhardt A M, Witzens M, Harig S, Hodi F S, Zauls A J, Chessia M, et al. Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood 2002; 100: 2123–2131
   PubMed Web of Science ®Google Scholar
• Lee S Y, Williamson B, Caballero O L, Chen Y T, Scanlan M J, Ritter G, et al. Identification of the gonad-specific anion transporter SLCO6A1 as a cancer/testis (CT) antigen expressed in human lung cancer. Cancer Immunol 2004; 4: 13
   PubMedGoogle Scholar
• Jager D, Karbach J, Pauligk C, Seil I, Frei C, Chen Y T, et al. Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes. Cancer Immunol 2005; 5: 11
   PubMedGoogle Scholar
• Okada T, Akada M, Fujita T, Iwata T, Goto Y, Kido K, et al. A novel cancer testis antigen that is frequently expressed in pancreatic, lung, and endometrial cancers. Clin Cancer Res 2006; 12: 191–197
   PubMed Web of Science ®Google Scholar